Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary)
Indications Autoimmune haemolytic anaemia
Focus Registrational; Therapeutic Use
Acronyms FORWARD
Sponsors Rigel Pharmaceuticals

Most Recent Events

01 Jan 2024 Results of post hoc analysis assessing efficacy of Fostamatinib for warm antibody autoimmune hemolytic anemia published in the American Journal of Hematology
10 Jan 2023 Status changed from active, no longer recruiting to completed.
13 Dec 2022 Primary endpoint has been met (Durable Hemoglobin Response) , according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com